HbA1c reductions at week 104 were -0.68 % , -0.72 % and -0.59 % for alogliptin 12.5 and 25 mg and glipizide , respectively [ both doses met the criteria for non-inferiority to glipizide ( p < 0.001 ) ; alogliptin 25 mg met superiority criteria ( p = 0.010 ) ] .